GSK agrees $10 billion deal for Nuvalent cancer drugs (opens in new tab)
Deal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline
Read the original articleDeal includes two late-stage molecules to augment GSK’s renewed cancer therapy pipeline
Read the original article